Scholar Rock has achieved a significant milestone with the FDA’s approval of Isembyld, the first therapy specifically targeting muscle loss in spinal muscular atrophy (SMA). This groundbreaking development offers renewed hope for patients suffering from this rare neurological disorder, potentially enhancing their ability to move and walk independently.
The FDA has sanctioned Isembyld for use in adults and children aged two and older who are already undergoing SMA treatments aimed at the SMN2 gene, which is crucial for motor neuron function. In a pivotal late-stage clinical trial, patients receiving Isembyld alongside an SMN2-targeting therapy exhibited notable improvements in motor skills after one year, contrasting sharply with the decline observed in the placebo cohort, a difference deemed statistically significant.
“Today’s FDA approval of Isembyld marks a defining moment for the SMA community,” stated David Hallal, CEO of Scholar Rock. He emphasized that after years of unsuccessful attempts within the industry to harness the potential of myostatin inhibition, Scholar Rock has finally delivered a therapeutic breakthrough. This approval not only represents a victory for the company but also sets a new precedent in the treatment landscape for SMA.
Use the database as your supply chain compass →
